Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. I: Structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patients

Diego V. Clé, Alexandre V. Hirayama, Alvaro J. Alencar, Luciano J. Costa, João V.P. Feliciano, Ederson R. Mattos, Ana C. Cordeiro, Marco Aurélio Salvino, George M.Navarro Barros, Marcos de Lima, Phillip Scheinberg, Renato L. Guerino-Cunha

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Chimeric antigen receptor T-cells (CAR-T cells) are a new modality of oncological treatment which has demonstrated impressive response in refractory or relapsed diseases, such as acute lymphoblastic leukemia (ALL), lymphomas, and myeloma but is also associated with unique and potentially life-threatening toxicities. The most common adverse events (AEs) include cytokine release syndrome (CRS), neurological toxicities, such as the immune effector cell-associated neurotoxicity syndrome (ICANS), cytopenias, infections, and hypogammaglobulinemia. These may be severe and require admission of the patient to an intensive care unit. However, these AEs are manageable when recognized early and treated by a duly trained team. The objective of this article is to report a consensus compiled by specialists in the fields of oncohematology, bone marrow transplantation, and cellular therapy describing recommendations on the Clinical Centers preparation, training of teams that will use CAR-T cells, and leading clinical questions as to their use and the management of potential complications.

Original languageEnglish (US)
Pages (from-to)S3-S12
JournalHematology, Transfusion and Cell Therapy
Volume43
DOIs
StatePublished - Nov 2021

Keywords

  • CAR-T cells
  • Cellular therapy
  • Center structuring
  • Complication management
  • Cytokine release syndrome
  • Neurotoxicity

ASJC Scopus subject areas

  • Immunology and Allergy
  • Hematology

Fingerprint

Dive into the research topics of 'Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. I: Structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patients'. Together they form a unique fingerprint.

Cite this